Asterion is developing a range of third-generation therapeutic proteins that will improve the current treatment options for patients with chronic diseases. Using its novel, patented ProFuseTM therapeutic platform Asterion is generating and developing long-acting biopharmaceutical products that can be administered at a lower dose, less frequently and with fewer side effects than existing marketed drugs.
Asterion is adopting a lower risk development strategy by developing third-generation Asterion Fusion Technology (AFTTM) therapeutic proteins that address unmet clinical and commercial needs in large markets where the targets are validated, the clinical development path is known and the commercial opportunity is clear.
These proprietary, best-in-class, third-generation, therapeutic products are being developed and commercialised through a combination of internal programmes and external collaborations.
Asterion’s most advanced product is a long-acting Growth Hormone agonist product for the treatment of growth disorders, which is being developed in a strategic alliance with Ipsen. Asterion also has internal programmes for other cytokine targets, which include erythropoietin (AFTTM - EPO), G-CSF (AFTTM – GCSF), interferons (AFTTM - Inteferon α ; AFTTM - Inteferon β) and leptin (AFTTM – Leptin), products which will be used to treat diseases such as anaemia, neutropenia, multiple sclerosis, growth disorders and autoimmune disorders.